Same dose as the first cohort who are no longer on the VAXINIA clinical trial due to pseudo progression, this was similarly observe for the case study of a TBNC on CHECKvacc who also discontinue the trial as there was PD.
OnCARlytics will be more effective against TBNC due to the expression of T Cell from these type of cancer.
IMU Price at posting:
3.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)